Palisade Short Long Term Debt vs Capital Surpluse Analysis

PALI Stock

USD 2.40 0.04 1.64%

Palisade Bio financial indicator trend analysis is much more than just breaking down Palisade Bio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Palisade Bio is a good investment. Please check the relationship between Palisade Bio Short Long Term Debt and its Capital Surpluse accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palisade Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.

Short Long Term Debt vs Capital Surpluse

Short Long Term Debt vs Capital Surpluse Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Palisade Bio Short Long Term Debt account and Capital Surpluse. At this time, the significance of the direction appears to have pay attention.

The correlation between Palisade Bio's Short Long Term Debt and Capital Surpluse is -0.8. Overlapping area represents the amount of variation of Short Long Term Debt that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Palisade Bio, assuming nothing else is changed. The correlation between historical values of Palisade Bio's Short Long Term Debt and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Long Term Debt of Palisade Bio are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Short Long Term Debt i.e., Palisade Bio's Short Long Term Debt and Capital Surpluse go up and down completely randomly.

Correlation Coefficient

-0.8

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Short Long Term Debt

The total of a company's short-term and long-term borrowings.

Capital Surpluse

Most indicators from Palisade Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Palisade Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palisade Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.As of now, Palisade Bio's Enterprise Value Multiple is increasing as compared to previous years.

	2021	2022	2023	2024 (projected)
Interest Expense	2.4M	13K	15K	14.3K
Depreciation And Amortization	168K	167K	4K	3.8K

Interest Expense Depreciation And Amortization

Palisade Bio fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Receivables
Total Assets		0.4	-0.2	0.37	0.75	0.4	0.05	-0.35	-0.35	0.49	0.82	0.39	-0.13	1.0	0.39	0.03	0.32	0.4	0.42	0.36	0.56	1.0	0.22	0.56	0.39	0.2
Short Long Term Debt Total	0.4		0.07	0.38	0.18	0.56	-0.29	0.34	0.02	0.39	0.17	0.46	-0.24	0.4	0.91	-0.34	0.26	0.22	-0.01	0.34	0.56	0.37	0.76	0.73	0.91	-0.33
Other Current Liab	-0.2	0.07		0.6	-0.66	0.35	0.12	0.13	0.45	0.44	-0.14	0.47	0.8	-0.23	-0.08	0.17	0.57	-0.13	-0.49	0.62	-0.26	-0.24	0.15	-0.25	-0.17	-0.13
Total Current Liabilities	0.37	0.38	0.6		-0.27	0.62	-0.09	0.17	0.03	0.74	0.24	0.74	0.58	0.33	0.27	-0.04	0.72	0.3	-0.05	0.89	0.15	0.33	0.62	0.27	0.21	-0.14
Total Stockholder Equity	0.75	0.18	-0.66	-0.27		0.05	0.17	-0.56	-0.4	-0.07	0.73	-0.17	-0.61	0.77	0.21	0.09	-0.35	0.38	0.48	-0.34	0.61	0.78	-0.04	0.39	0.25	0.32
Property Plant And Equipment Net	0.4	0.56	0.35	0.62	0.05		-0.03	0.14	-0.15	0.61	0.18	0.65	0.25	0.35	0.4	0.02	0.33	0.46	0.15	0.48	0.74	0.36	0.55	0.39	0.33	0.16
Current Deferred Revenue	0.05	-0.29	0.12	-0.09	0.17	-0.03		-0.44	0.09	-0.36	0.22	-0.21	0.08	0.07	-0.25	0.94	-0.28	0.13	-0.06	-0.24	0.02	0.07	-0.26	-0.4	-0.27	-0.02
Net Debt	-0.35	0.34	0.13	0.17	-0.56	0.14	-0.44		0.09	0.15	-0.74	0.23	0.08	-0.36	0.42	-0.46	0.38	-0.17	-0.15	0.32	-0.13	-0.38	0.29	0.22	0.42	-0.4
Retained Earnings	-0.35	0.02	0.45	0.03	-0.4	-0.15	0.09	0.09		0.02	-0.21	-0.33	0.24	-0.34	0.08	0.12	0.06	-0.23	-1.0	0.05	-0.39	-0.34	-0.06	-0.61	0.01	-0.03
Accounts Payable	0.49	0.39	0.44	0.74	-0.07	0.61	-0.36	0.15	0.02		0.23	0.65	0.5	0.45	0.24	-0.32	0.76	0.07	-0.01	0.82	0.19	0.45	0.36	0.3	0.18	0.12
Cash	0.82	0.17	-0.14	0.24	0.73	0.18	0.22	-0.74	-0.21	0.23		0.15	-0.11	0.82	0.13	0.17	0.03	0.42	0.28	0.13	0.42	0.83	0.11	0.29	0.13	0.26
Non Current Assets Total	0.39	0.46	0.47	0.74	-0.17	0.65	-0.21	0.23	-0.33	0.65	0.15		0.54	0.35	0.34	-0.14	0.7	0.01	0.31	0.77	0.24	0.32	0.46	0.59	0.29	-0.05
Non Currrent Assets Other	-0.13	-0.24	0.8	0.58	-0.61	0.25	0.08	0.08	0.24	0.5	-0.11	0.54		-0.18	-0.28	0.14	0.64	-0.22	-0.28	0.65	-0.4	-0.18	-0.08	-0.31	-0.38	0.2
Cash And Short Term Investments	1.0	0.4	-0.23	0.33	0.77	0.35	0.07	-0.36	-0.34	0.45	0.82	0.35	-0.18		0.4	0.03	0.29	0.36	0.41	0.33	0.54	1.0	0.2	0.56	0.4	0.15
Common Stock Total Equity	0.39	0.91	-0.08	0.27	0.21	0.4	-0.25	0.42	0.08	0.24	0.13	0.34	-0.28	0.4		-0.3	0.26	0.24	-0.07	0.29	0.45	0.38	0.61	0.65	0.99	-0.25
Common Stock Shares Outstanding	0.03	-0.34	0.17	-0.04	0.09	0.02	0.94	-0.46	0.12	-0.32	0.17	-0.14	0.14	0.03	-0.3		-0.26	0.1	-0.09	-0.21	0.0	0.04	-0.3	-0.47	-0.34	0.07
Non Current Liabilities Total	0.32	0.26	0.57	0.72	-0.35	0.33	-0.28	0.38	0.06	0.76	0.03	0.7	0.64	0.29	0.26	-0.26		-0.15	-0.08	0.95	-0.2	0.27	0.18	0.26	0.2	-0.17
Other Current Assets	0.4	0.22	-0.13	0.3	0.38	0.46	0.13	-0.17	-0.23	0.07	0.42	0.01	-0.22	0.36	0.24	0.1	-0.15		0.25	0.04	0.65	0.41	0.41	0.2	0.22	0.25
Other Stockholder Equity	0.42	-0.01	-0.49	-0.05	0.48	0.15	-0.06	-0.15	-1.0	-0.01	0.28	0.31	-0.28	0.41	-0.07	-0.09	-0.08	0.25		-0.07	0.43	0.41	0.04	0.62	0.0	0.07
Total Liab	0.36	0.34	0.62	0.89	-0.34	0.48	-0.24	0.32	0.05	0.82	0.13	0.77	0.65	0.33	0.29	-0.21	0.95	0.04	-0.07		-0.06	0.31	0.39	0.3	0.23	-0.17
Property Plant And Equipment Gross	0.56	0.56	-0.26	0.15	0.61	0.74	0.02	-0.13	-0.39	0.19	0.42	0.24	-0.4	0.54	0.45	0.0	-0.2	0.65	0.43	-0.06		0.56	0.47	0.54	0.45	0.2
Total Current Assets	1.0	0.37	-0.24	0.33	0.78	0.36	0.07	-0.38	-0.34	0.45	0.83	0.32	-0.18	1.0	0.38	0.04	0.27	0.41	0.41	0.31	0.56		0.19	0.53	0.38	0.21
Short Term Debt	0.22	0.76	0.15	0.62	-0.04	0.55	-0.26	0.29	-0.06	0.36	0.11	0.46	-0.08	0.2	0.61	-0.3	0.18	0.41	0.04	0.39	0.47	0.19		0.58	0.61	-0.38
Intangible Assets	0.56	0.73	-0.25	0.27	0.39	0.39	-0.4	0.22	-0.61	0.3	0.29	0.59	-0.31	0.56	0.65	-0.47	0.26	0.2	0.62	0.3	0.54	0.53	0.58		0.71	-0.27
Common Stock	0.39	0.91	-0.17	0.21	0.25	0.33	-0.27	0.42	0.01	0.18	0.13	0.29	-0.38	0.4	0.99	-0.34	0.2	0.22	0.0	0.23	0.45	0.38	0.61	0.71		-0.33
Net Receivables	0.2	-0.33	-0.13	-0.14	0.32	0.16	-0.02	-0.4	-0.03	0.12	0.26	-0.05	0.2	0.15	-0.25	0.07	-0.17	0.25	0.07	-0.17	0.2	0.21	-0.38	-0.27	-0.33

Click cells to compare fundamentals

Palisade Bio Account Relationship Matchups

Palisade Bio fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	6.6M	3.0M	12.5M	15.8M	14.1M	12.3M
Other Current Liab	368.0K	4.3M	862K	1.1M	1.6M	1.5M
Total Current Liabilities	1.2M	8.1M	2.5M	3.0M	2.6M	3.4M
Total Stockholder Equity	5.1M	(16.6M)	7.4M	12.5M	11.3M	6.2M
Property Plant And Equipment Net	242.7K	280K	112K	310K	208K	233.1K
Net Debt	(4.9M)	708K	(10.3M)	(12.0M)	(12.1M)	(11.5M)
Retained Earnings	(222.0M)	(68.0M)	(94.6M)	(109.2M)	(121.5M)	(127.6M)
Accounts Payable	824.4K	2.5M	1.3M	1.8M	698K	663.1K
Cash	5.1M	713K	10.5M	12.4M	12.4M	8.5M
Non Current Assets Total	937.0K	2.1M	138K	1.0M	724K	1.1M
Non Currrent Assets Other	25.3K	1.8M	26K	694K	516K	321.3K
Cash And Short Term Investments	5.1M	713K	10.5M	12.4M	12.4M	10.4M
Common Stock Total Equity	151.6K	182.1K	38.7K	173.0K	155.7K	147.9K
Common Stock Shares Outstanding	488.32	55.5K	12.5K	58.7K	456.0K	478.8K
Liabilities And Stockholders Equity	6.6M	3.0M	12.5M	15.8M	14.1M	12.3M
Non Current Liabilities Total	233.1K	11.5M	2.7M	272K	153K	145.4K
Other Current Assets	510.9K	124K	861K	912K	748K	542.6K
Other Stockholder Equity	227.1M	60.9M	102.0M	121.6M	132.7M	140.2M
Total Liab	1.5M	19.6M	5.1M	3.3M	2.7M	2.6M
Property Plant And Equipment Gross	268.1K	10.8K	112K	310K	208K	218.2K
Total Current Assets	5.6M	896K	12.4M	14.7M	13.3M	11.2M
Intangible Assets	883.5K	763.5K	668.9K	147.1K	169.2K	160.7K
Common Stock	38.7K	28K	143K	30K	93K	88.4K
Net Receivables	21.1K	59K	150K	1.4M	148K	264.5K
Other Assets	13.9K	24.0K	26K	157.6K	29.9K	48.2K
Capital Surpluse	217.1M	219.5M	227.1M	247.8M	285.0M	245.4M
Property Plant Equipment	5K	420K	280K	112K	100.8K	167.9K

Currently Active Assets on Macroaxis

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America
S	SentinelOne
WD	Walker Dunlop

When determining whether Palisade Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Palisade Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Palisade Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Palisade Bio Stock:

How To Invest In Palisade

Details

Is Palisade Stock a good investment?

Details

What is Palisade Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Palisade Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For more detail on how to invest in Palisade Stock please use our How to Invest in Palisade Bio guide.

You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Palisade Bio. If investors know Palisade will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Palisade Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(13.26)

Return On Assets

(0.59)

Return On Equity

(1.10)

The market value of Palisade Bio is measured differently than its book value, which is the value of Palisade that is recorded on the company's balance sheet. Investors also form their own opinion of Palisade Bio's value that differs from its market value or its book value, called intrinsic value, which is Palisade Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Palisade Bio's market value can be influenced by many factors that don't directly affect Palisade Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Palisade Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Palisade Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Palisade Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Palisade Short Long Term Debt vs Capital Surpluse Analysis

Short Long Term Debt vs Capital Surpluse

Short Long Term Debt vs Capital Surpluse Correlation Analysis

Correlation Coefficient

Short Long Term Debt

Capital Surpluse

Palisade Bio fundamental ratios Correlations

Palisade Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Palisade Bio fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Cash And Short Term Investments
Common Stock	+ 0.99	Common Stock Total Equity
Total Liab	+ 0.95	Non Current Liabilities Total
Common Stock Shares Outstanding	+ 0.94	Current Deferred Revenue

Other Stockholder Equity	- 1.0	Retained Earnings
Cash	- 0.74	Net Debt
Total Stockholder Equity	- 0.66	Other Current Liab
Intangible Assets	- 0.61	Retained Earnings
Non Currrent Assets Other	- 0.61	Total Stockholder Equity
Net Debt	- 0.56	Total Stockholder Equity